The present study shows that recombinant human megakaryocyte growth and development factor (r-HuMGDF) behaves both as a megakaryocyte colony stimulating factor and as a differentiation factor in human progenitor cell cultures. Megakaryocyte colony formation induced with r-HuMGDF is synergistically affected by stem cell factor but not by interleukin 3. Megakaryocytes stimulated with r-HuMGDF demonstrate progressive cytoplasmic and nuclear maturation. Measurable levels of megakaryocyte growth and development factor in serum from patients undergoing myeloablative therapy and transplantation are shown to be elaborated in response to thrombocytopenic stress. These data support the concept that megakaryocyte growth and development factor is a physiologically regulated cytokine that is capable of supporting several aspects of megakaryopoiesis. 
Introduction
The hematopoietic factor(s) directing the processes of megakaryocyte development and platelet formation have been the object of intense study for nearly 40 yr (1, 2) . Traditionally, regulation of this lineage has been attributed to separate factors controlling growth (megakaryocyte colony-stimulating factors, Meg-CSF') versus differentiation (thrombopoietin, TPO) (3) (4) (5) (6) (7) (8) (9) (10) . Recently, reports concerning c-mpl, a gene encoding a cytokine receptor expressed on CD34+ cells, megakaryocytes, and platelets (11, 12) strongly suggested that the unknown ligand for this receptor might be an important megakaryocyte regulatory cytokine. This has now been confirmed by several groups that have cloned and expressed the gene for this new factor (13) (14) (15) (16) . This cytokine has been named: TPO invoking the historical name for a platelet-forming factor (15) , Mpl ligand (ML) to reflect the ligand/receptor relationship with Mpl (14) , or megakaryocyte growth and development factor (MGDF), to reflect the multiple biological properties of the molecule (13) .
The in vitro characterization of the recombinant, human form of this cytokine (r-HuMGDF) on human megakaryopoiesis is presented here. r-HuMGDF behaves both as a meg-CSF and as a megakaryocyte maturation factor (TPO) on human CD34+ cells. Measurable levels of MGDF in serum collected from patients undergoing myeloablative therapy and transplantation demonstrate the physiological relevance of this molecule. These data support the concept that all of the megakaryopoietic and thrombopoietic activities present in plasma, sera, or urine from models of bone marrow aplasia or thrombocytopenia (2, 11, (17) (18) (19) (20) can be substantially, if not wholly, accounted for by the cytokine MGDF.
Methods
Human subjects. Normal (5) and averaged 90±5% (n = 12, range from 81 to 96%). Cells were aliquoted and frozen until use (5) .
Megakaryocyte colony-forming assay. Colony forming units megakaryocyte (CFU-meg) were detected by a modification of the plasma clot assay (17) . CD34+ cells were plated in triplicate wells of 24-well tissue culture plates from Falcon Labware (Lincoln Park, NJ) at the indicated cell concentration. Culture media consisted of 15% citrated, platelet-poor, human AB plasma in Iscove's modified Dulbecco's me-dium from GIBCO BRL (Grand Island, NY) with designated growth factors and additives as described (21) . Megakaryocyte colonies were stained with antibodies to GPIb and GPIIb/I[la from BIODESIGN International (Kennebunkport, ME) and a secondary goat-anti-mouse conjugated with FITC from Southern Biotechnology Associates, Inc. (Birmingham, AL). Nuclei were counter-stained with propidium iodide (PI) at 2.5 ug/ml from Sigma Chemical Co. (St. Louis, MO) in 0.1I% citrate. Colonies were defined as three or more brightly green fluorescent cells by inverted fluorescent microscopy from Olympus Corp. (Lake Success, NY) at x 100 magnification. Photomicrographs were obtained on a PM-20 microphotography system also from Olympus Corp.
Liquid culture of megakaryocyte progenitors. Megakaryocyte cultures were established as previously described (5) Evaluation of MGDF in human patient sera. Serum samples were collected and platelet counts taken from patients with lymphoid malignancies: non-Hodgkin's lymphoma (n = 6), acute lymphoblastic leukemia (n = 4), and Hodgkin's disease (n = 1). Patients were treated (day -7 through -2) with high dose busulfan and cyclophosphamide before transplant with autologous peripheral blood progenitor cells with (n = 9) or without (n = 2) autologous bone marrow on day 0. All patients received Filgrastim (G-CSF) during the recovery period (23, 24) . At the time of the treatment serum was separated, aliquoted, and stored frozen at -80°C. Serum MGDF levels were measured in the thawed samples with factor-dependent murine cells expressing human c-mpl (32D/huMpl+ cells) as described (13 Cytokine combinations. r-HuMGDF was examined alone in combination with SCF or LL-3 for effects on megakaryocyte colony formation. Preliminary experiments were performed to determine the optimal concentration of each cytokine. Each cytokine was also tested alone for its megakaryocyte colony stimulating ability. SCF, which did not induce colony formation at any concentration tested, was used at 50 ng/ml. IL-3 was used at the maximally effective concentration of 10 ng/ml and r-HuMGDF was used in a dose range from 0.1 to 100 ng/ml.
The effects of these cytokines on colony number are shown in Fig. 3 . In this experiment, IL-3 induced 12±2 colonies. rHuMGDF maximally induced from 120 to 140 colonies. However, the combination of r-HuMGDF and 11L-3 resulted in fewer colonies than induced with r-HuMGDF alone. This type of "inhibitory" response was seen in two experiments. In two other experiments of equivalent design, the cytokine combination resulted in a number of colonies that was more than observed with either individual factor, but less than the additive number. In no case was a synergistic reaction observed. This was in contrast to the result of combining r-HuMGDF with SCF where, in four independent experiments, the combination consistently resulted in more colonies (120-200%) then generated with rHuMGDF alone.
The effects of these cytokines on colony size (megakaryocytes per colony) are shown in Fig. 4 (Fig. 5 C) . The ploidy profile clearly shows evidence of continued endomitotic activity 2974 Nichol et al. in the population as the main ploidy peaks have shifted to 4N and 8N and 16N and 32 N peaks have become more prominant (Fig. 5 F) .
Serum MGDF levels in thrombocytopenic patients. Platelet levels and serum MGDF levels were determined in a population of patients treated with myeloablative therapy (day -7 through -2) and progenitor cell transplant (day 0) (Fig. 6) . All of the patients exhibited a period of severe thrombocytopenia (days 5-10) followed by a rise in platelet counts as engraftment occurred. In all 11 of the patients evaluated, serum MGDF levels were low to undetectable through the treatment period, then rose and peaked during the thrombocytopenic nadir. MGDF levels dropped after this point and slowly returned toward baseline levels. Although all of the patients showed the same pattern over the time course, the absolute MGDF levels a: in 50 ng/ml r-HuMGDF. varied considerably between patients. Levels ranged from 0 to 3,200 U/ml in the treatment phase and rose to from 1,600 to 102,400 U/ml during the peak phase. Because of this variation, MGDF levels within each patient series were calculated as the percentage of the maximum value seen in that patient series.
Discussion
The activity of r-HuMGDF on human CD34+ cells is consistent with that expected for a lineage-restricted, megakaryocyte colony-stimulating factor. Colonies of 3-30 megakaryocytes were observed with 12 d of culture, an accepted standard for this type of factor (25) . r-HuMGDF appears to function without accessory cell contribution since the relationship between the number of CD34+ cells plated to the number of colonies formed was measured as a function of r-HuMGDF concentration (0.1-10 ngl ml). All colonies in the culture well were evaluated (0.1 ng/ml, n = 5; at 0.5 ng/ml, n = 63; at 1 ng/ml; n = 70; at 5 ng/ml, n = 50, at 10 ng/ml, n = 70). (B) Cytokine combinations were examined for effects on colony size. IL-3 (10 ng/ml) or SCF (50 ng/ml) were added to cultures containing r-HuMGDF (10 ng/ml). All colonies in the culture well were evaluated (n = 37, MGDF; n = 21, IL-3; n = 0, SCF; n = 52, MGDF + IL3; n = 43, MGDF + SCF). Data are expressed as the mean of multiple data points±SEM. This experiment is representative of three identical experiments.
was constant, even at low cell density. This function of rHuMGDF was also not dependent on plasma-derived cofactors since megakaryocyte colony formation could also be observed in the serum-depleted fibrin clot assay described by Bruno et al. (26) (Briddell, R. personal communication). r-HuMGDF, like other lineage-restricted colony stimulating factors (27, 28) , is synergistic with the earlier acting factor, SCF. The MGDFresponsive progenitor cell has been partially characterized. It is a mononuclear cell of 8-10 gm in diameter with a large nuclear/cytoplasmic ratio. In earlier studies, using a plasma source of MGDF, the phenotype was defined as CD34+ / CD38+ and CD34+/HLADR+. Responsive cells were also included in both CD34+/CD41 + and CD34+/CD41-populations (5).
The activity of r-HuMGDF on human CD34+ cells is also consistent with that expected for a megakaryocyte differentiation factor (29, 30) . r-HuMGDF was sufficient to induce the development of progenitor cell populations into stage IV megakaryocytes exhibiting classic features of eosinophilic granulation and nuclear condensation and eccentricity. Endomitotic activity, another in vitro parameter of maturity (29, 31, 32) was also evident in these cultures. In addition, r-HuMGDF-induced megakaryocytes are fully competent to complete the natural life cycle of this lineage, which is to fragment into functional platelets (Choi, E. S., M. Hokom, T. Bartley, Y.-S. Li, H. Oh-shi, T. Kato, J. L. Nichol, J. Skrine, A. Knudten, J. Chen, et al., manuscript submitted for publication). These data are in full agreement with published reports on the ability of this molecule to raise the platelet counts of recipient animals (14, 15) .
The concept that factor(s) present in aplastic sera control both mitosis and endomitosis has previously been suggested by Arriaga et al. in 1987 (25) , and more recently by Wendling et al. (33) and de Sauvage et al. (14) . Other hematopoietic cytokines such as macrophage colony-stimulating factor, interleukin 5, erythropoietin, and granulocyte colony-stimulating factor (34) (35) (36) have also been shown to stimulate not only growth but also differentiation of their target cells. Although the exact mechanism for the dual function of MGDF has yet to be determined, this could involve stimulation of alternative tyrosine kinase pathways (35) or be accomplished through occupation of specific regions of the receptor (36 MGDF is a cytokine present in several experimental models of bone marrow aplasia (13) (14) (15) (16) . Therefore, it was of interest to consider the relationship between serum MGDF and platelet levels in a patient population that experiences severe, but reversible, thrombocytopenia. In myeloablated patients undergoing progenitor cell transplant, the platelet nadir was always associated with the peak of serum MGDF which returned towards baseline as platelet counts recovered. This time course is consistent with earlier work that tracked megakaryopoietic activity in similarly compromised patients (38) . The peak levels produced (1,600-102,400 U/ml) were sufficient to support in vitro colony formation. The mean unit value of aplastic canine plasma, a potent source of megakaryocyte colony stimulating activity (13, 17) , is 4,222±353 U/ml. Although it is tempting to calculate the MGDF protein concentrations in these samples, it would not be accurate to do so. Interfering substances present in serum make this a semiquantitative assay. The development of specific immunoassays will allow direct measurement of MGDF levels.
The data presented here support the concept that MGDF acts on at least two aspects of megakaryocyte development, growth, and maturation. MGDF is also elaborated into the plasma of patients experiencing thrombocytopenic stress in a manner that implies it is responding to this stress. These data suggest that MGDF is a physiologically regulated cytokine that is capable of supporting several aspects of megakaryopoiesis.
